Intravenous catheter infections in pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 62, Issue SUPPL.160, 2008, Pages 3-4

  Gaine, S ^a   Gomberg Maitland, M ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; UNIPROST;

CATHETER INFECTION; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG INFUSION; EDITORIAL; EDUCATION; FOLLOW UP; GRAM NEGATIVE ANAEROBIC BACTERIA; HUMAN; INTRAVENOUS CATHETER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE;

EID: 47349127375     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01810.x     Document Type: Editorial

References (10)

1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976 263 : 663 5.
2. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984 1 : 1046 7.
3. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 334 : 296 302.
4. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 132 : 425 34.
5. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999 130 : 740 3.
6. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999 99 : 1858 65.
7. Humbert M, Sanchez O, Fartoukh M et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999 13 : 1351 6.
8. Oudiz RJ, Widlitz A, Beckmann XJ et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004 126 : 90 4.
9. Moureau N, Poole S, Murdock MA et al. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol 2002 13 : 1009 16.
10. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007 56 : 170 2.